Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.460
0.00 (0.00%)
Oct 31, 2025, 10:35 AM EDT - Market open
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $108.79 million as of October 31, 2025. Its market cap has increased by 616.26% in one year.
Market Cap
108.79M
Enterprise Value
21.17M
1-Year Change
616.26%
Ranking
Category
Stock Price
$1.46
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $108.79M, an increase of 8.30%. That is a compound annual growth rate of 1.66%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Oct 30, 2025 | 108.79M | -50.18% |
| Dec 31, 2024 | 218.38M | 2,684.93% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | 69.35M | -30.96% |
| Dec 23, 2020 | 100.46M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 731.65B |
| Johnson & Johnson | 449.95B |
| AbbVie | 401.32B |
| UnitedHealth Group | 337.95B |
| AstraZeneca | 259.35B |
| Novartis AG | 250.89B |
| Novo Nordisk | 235.38B |
| Abbott Laboratories | 220.22B |